The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities.
Ottmann
Oliver G
OG
Medizinische Klinik III, Department of Hematology and Oncology, Johann Wolfgang Goethe-Universität, Frankfurt, Germany. ottman@em.uni-frankfurt.de
Hoelzer
Dieter
D
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000592:standards / Q000627:therapeutic use*; D001549:Benzamides; D004351:Drug Resistance; D016044:Fusion Proteins, bcr-abl / Q000187:drug effects / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000008:administration & dosage / Q000592:standards / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000008:administration & dosage / Q000592:standards / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl